Alembic Pharmaceuticals gains FDA approval for Icatibant Injection
Alembic Pharmaceuticals Limited has achieved a significant milestone with the US Food & Drug Administration’s (USFDA) final approval of its Abbreviated New Drug Application (ANDA) for Icatibant Injection, used in the treatment of acute attacks of hereditary angioedema (HAE) in adults. This approval marks the first peptide product approval for Alembic, showcasing their commitment to […]